First published in Diabetes Technology & Therapeutics on 2010 Aug.Diabetes Technol Ther. 2010 Aug;12(8):599-604. doi: 10.1089/dia.2010.0019 Authors: Pfützner A, Derwahl...
Read Article
This open-label, nonrandomized, single-dose, phase 1 study evaluated the pharmacokinetics and safety of murepavadin, a novel peptide antibiotic for the treatment of serious Pseudomonas aeruginosa infections.
This open-label, nonrandomized, single-dose, phase 1 study evaluated the pharmacokinetics and safety of murepavadin, a novel peptide antibiotic for the treatment of serious Pseudomonas aeruginosa infections.
Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) receptor agonists, improve glycaemic control and reduce weight in patients with type 2 diabetes. I